Prostate Cancer

Update: On June 16, 2021, Novartis announced that  177 Lu-PSMA-617 received Breakthrough Therapy designation from the FDA. The designation is used to help speed the development and review of therapies that demonstrate the potential to be a substantial improvement over available treatments. On June 23, 2021, trial results were published in the New England Journal of Medicine . Dr. Morris presented these data on June 6, at the annual meeting of the American Society of Clinical Oncology. Prostate cancer treatment stands on the brink of a major advance with the development of a new treatment that zeros in on cancer cells to destroy them. The therapy, called 177 Lu-PSMA-617, uses a molecule that selectively seeks out and attaches to a specific protein on the cancer cell surface. The technology then delivers radiation that damages DNA and destroys the cancer cell. This treatment can find and demolish cancer cells that are resistant to other therapies. The emergence of the new treat

Diindolylmethane supplements have surged in popularity in recent years. Today, many people take diindolylmethane (DIM) supplements for testosterone, cancer, weight loss, acne, or hormones. As WebMD explains, DIM appears to help destroy cancer cells and reduce swelling. Diindolylmethane sounds like a complex chemical. But it's not. Your body makes diindolylmethane on its own from a chemical called indole-3-carbinol, which is a natural component of broccoli, cauliflower, and other cruciferous vegetables. Today, the best DIM supplements let you enjoy the benefits of diindolylmethane without requiring you to eat multiple heads of broccoli or cauliflower. The Top Diindolylmethane (DIM) Product Brands in 2022 We're diindolylmethane (DIM) supplement experts. To compile the rankings below, our editorial team conducted hundreds of hours of research, contacted the best DIM supplement manufacturers, and pored over research studies. After much deliberation, h

This article was originally published here Surg Today. 2022 Feb 24. doi: 10.1007/s00595-022-02485-9. Online ahead of print. ABSTRACT PURPOSE: To establish the prognostic significance of C-reactive protein (CRP) and albumin in octogenarians with non-small cell lung cancer (NSCLC) based on the study of the Japanese Association for Chest Surgery (JACS 1303). METHODS: A total of 618 octogenarians with pathological stage I NSCLC, who underwent pulmonary resection, were included in the analysis. We conducted multivariable Cox regression analysis to evaluate the CRP to albumin ratio (CAR) as a potential prognostic factor. Other clinicopathological factors were also evaluated. RESULTS: The median age was 82 years. Operations included lobectomy (n = 388; 62.8%) segmentectomy (n = 95; 15%), and wedge resection (n = 135; 22%). Pathological stage IA was diagnosed in 380 (61.5%) patients. The 3-year (OS) and cancer-specific survival (CS) rates were 86.7% and 94.6%, respectively. O

Introduction Prostate cancer (PCa) is the most common noncutaneous cancer in men in the United States. Approximately 191,930 men will be diagnosed and 33,330 men will die from PCa in 2020. 1 With the introduction of widespread prostate-specific antigen (PSA) screening, most men are diagnosed at the localized PCa stages. Several well-established treatment options, such as radical prostatectomy, radiation therapy, and whole-gland cryotherapy, are available for localized PCa. Although these treatment modalities are highly effective in providing a cure at the localized stage, they are often associated with debilitating adverse effects (AEs) such as erectile dysfunction and urinary incontinence. As a result, patients often delay or defer treatment of their PCa altogether. In the past decade, active surveillance (AS) has increased for low- and very low-risk PCa, which has reduced overtreatment and sequelae of definitive treatment. However, as noted in the PROTECT trial, approximately 50% of